Altre lingue Surrozen, Inc.

Azioni

SRZN

US86889P2083

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
8,97 ^USD	-0,44%		-4,17%	-4,57%

10/04	Surrozen, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
08/04	L'insider di Surrozen ha acquistato azioni per un valore di 2.999.994 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	08/04
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.	04/04
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis	03/04
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043	01/04
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules	01/04
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	01/04
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding	01/04
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer	07/02
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	18/01
Sector Update: Health Care Stocks Weaker Thursday Afternoon	18/01
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall	18/01
Surrozen Provides Corporate Update on Clinical Programs	18/01
Surrozen, Inc. Provides Corporate Update on Clinical Programs	18/01
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Surrozen Provides Third Quarter 2023 Financial Results	08/11
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	08/11
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Surrozen Provides Second Quarter 2023 Financial Results	09/08/23
Surrozen, Inc. Announces Management Changes	19/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Surrozen, Inc.

Azioni

SRZN

US86889P2083

Altre lingue

Filtri